A program to build supersonic trainer aircraft is to be officially launched today, with the first prototype expected in two years, and flight tests a year later.
Air Force Commander General Shen Yi-ming (沈一鳴) and Chung-shan Institute of Science and Technology president Chang Guan-chung (張冠群) are to sign a memorandum to award the institute an NT$68.6 billion (US$2.22 billion) contract to build 66 planes.
A cornerstone of President Tsai Ing-wen’s (蔡英文) policy to develop a local defense industry, the program is to produce 66 XT-5 “Blue Magpie” trainers designed by Aerospace Industrial Development Corp (AIDC) to replace the air force’s aging AT3 trainers and F5 fighters, which remain in service to support training exercises.
AIDC, the main subcontractor, has gathered more than 300 aviation professionals to design and produce the new trainer, which is reportedly based on the design of Indigenous Defense Fighter (IDF) jets assembled by AIDC.
The IDF was produced with the technical assistance of several US companies, including General Dynamics Corp, which helped with the frame; Hughes Corp, which designed the engine; and Westinghouse Co, which produced the avionics system.
AIDC is to design models to undergo wind tunnel testing in the US and other tests in Taiwan, with the first Blue Magpie prototype to be built by 2019 and the first trial flight set for 2020.
The first Blue Magpie is also scheduled to be commissioned that year, with the fleet of 66 XT-5s projected to be completed in 2028.
The air force first submitted a budget in 2008 to procure new trainer jets to replace the AT3s, which have a recommended service life of 20 years and were nearing the end of that time frame.
The Alenia Aermacchi M-346 trainers made by Italy’s Leonardo-Finmeccanica and T50 trainers developed by a South Korean company as well as the US’ Lockheed Martin were the primary objectives.
Following test trials of the M-346, the air force submitted a NT$69.1 billion budget to purchase 66 of the planes and a memorandum was signed between AIDC and Leonardo-Finmeccanica to manufacture four to six M-346s in Italy, with the rest to be built in Taiwan.
However, the procurement project was shelved following the election of President Tsai Ing-wen (蔡英文), who had pledged to make the defense industry one of Taiwan’s key economic drivers.
Leonardo-Finmeccanica did offer a substantially reduced price — cutting its bill from NT$69.1 billion to NT$50.4 billion — but the government decided to maintain its pledge to build a locally developed plane.
Additional reporting by staff writer
PRIORITY GROUPS: A line of people were waiting at the Good Liver Clinic, apparently to get shots, while the CECC announced more priority groups for jabs The Taipei-based Good Liver Clinic is to be fined NT$2 million (US$72,028) after giving free COVID-19 vaccine shots to people not in groups eligible to receive them, Taipei Deputy Mayor Vivian Huang (黃珊珊) said yesterday. The Zhongshan District (中山)-based clinic was removed from the city’s list of vaccination venues and health officials would be investigated for giving 1,113 doses to the clinic, Huang told an afternoon news conference at Taipei City Hall. The Chinese-language Liberty Times (the Taipei Times’ sister paper) on Tuesday in an exclusive story citing an anonymous tip reported that a Taipei clinic was doling out unused vaccines. People in
‘GOOD SIGN’: Thanks to public efforts, the number of COVID-19 cases is on a downward trend, the minister of health said, but told people not to let their guard down The COVID-19 situation appears to be relatively stable and on a downward trend, Minister of Health and Welfare Chen Shih-chung (陳時中) said yesterday, as he reported 185 domestic COVID-19 cases and 15 deaths. “This seems to be a relatively good sign,” Chen, who heads the Central Epidemic Command Center (CECC), told a daily news briefing. In Taipei and New Taipei City, the overall situation seems to be heading in a good direction, he added. He attributed it to public efforts to control the spread of the virus, but warned people against letting their guard down. Of the new local cases, 83 are males and
PHASE 2: The firm’s CEO said that the results were good and the experimental vaccine safe, but added that hoped-for phase 3 trials would be expensive Medigen Vaccine Biologics Corp (高端疫苗) yesterday reported positive results from an interim analysis of phase 2 trials for its COVID-19 vaccine, saying that the vaccine demonstrated high seroconversion rates and geometric mean titer (GMT) figures. A seroconversion rate is the percentage of participants in a trial displaying virus-specific immune memory after being given a vaccine, while the GMT measures the level of neutralizing antibody response, Medigen said. The experimental vaccine has a seroconversion rate of 99.8 percent and its GMT was 662 among the participants aged 20 to 89, while the gauges rose to 99.9 percent and 733 respectively in participants aged
ROLLING OUT DOSES: The expansion aims to speed up Taiwan’s vaccination drive by making more Moderna jabs available to workers at hospitals, the CECC said The Central Epidemic Command Center (CECC) yesterday expanded the eligibility for the Moderna COVID-19 vaccine to all healthcare workers and non-healthcare workers in the highest vaccine priority group. The center said that 75,000 doses of the vaccine — half of the first batch Taiwan has received — were on Wednesday distributed to hospitals across the nation with specialized COVID-19 rooms, negative pressure wards and testing services. Thus far, they had only been offered to frontline healthcare workers and non-healthcare workers at the designated hospitals, it said. Minister of Health and Welfare Chen Shih-chung (陳時中), who heads the center, said that the eligibility was